This article presents recommendations developed by the Atopic Dermatitis Group of the Portuguese Society of Dermatology and Venereology addressing several clinical questions that arise in the management and care of moderate-tosevere atopic dermatitis with biologic agents and Janus kinase inhibitors based on the available evidence.
This article reviews the role of IL-13 in atopic dermatitis and the most recent data on lebrikizumab and tralokinumab.
The present paper reviews the data of dupilumab-associated conjunctivitis and risk factors in adults with moderate-to-severe AD and other atopic diseases in dupilumab clinical trials and addresses the characteristics and treatment options available for this clinically highly relevant condition.
AD is often complicated and difficult to manage in many Asian cities and effective therapy is impeded by fallacies. In this article eleven anonymized case scenarios are described to illustrate issues associated with these fallacies. A literature review is performed and possible solutions to handle or dismiss these fallacies are discussed.
